![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of a simplified subcutaneous
lenacapavir regimen versus Phase 2/3 regimen
|
|
|
AIDS 2022 July 29-Aug 1 Montreal
Presenter
Vamshi Jogiraju
Authors
V. Jogiraju * (1), H. Graham (1), S. West (1), J. Ling (1), J. Cuvin (1), M. Rhee (1), R. Palaparthy (1), R. Singh (1)
Institutions
(1) Gilead Sciences, Inc., Foster City, United States
![0804221copy](../images/080522/080522-5/0804221copy.gif)
![0804222copy](../images/080522/080522-5/0804222copy.gif)
![0804223copy](../images/080522/080522-5/0804223copy.gif)
![0804224copy](../images/080522/080522-5/0804224copy.gif)
![0804225copy](../images/080522/080522-5/0804225copy.gif)
![0804226copy](../images/080522/080522-5/0804226copy.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|